The earliest events following mucosal HIV-1 exposure represent a critical window of opportunity for vaccine-elicited immune responses to impact the acquisition and propagation of HIV-1 infection. However, very little is known about the biology of the eclipse phase of HIV-1 infection in humans, particularly the immunologic and virologic events that occur at the mucosal site of transmission. Given the difficulties in studying the earliest mucosal events of HIV-1 infection in humans, modeling these events in nonhuman primates is required. Such studies will provide insight into the early events of virus transmission and the capacity of immune responses to block or to attenuate these events. In this Project, we hypothesize that SIV-specific immune responses elicited by adenovirus and poxvirus vaccine vectors will substantially impact the early events following intravaginal (IVAG) SIV infection of rhesus monkeys. In particular, we hypothesize that vaccine-elicited mucosal immune responses at the site of inoculation will limit the initial local amplification of virus at the mucosal portal of entry during the eclipse phase of infection prior to systemic virus dissemination. The goal is to define precisely when and where innate and adaptive immune responses intercept the virus following IVAG SIV infection of both .naive and vaccinated animals. To evaluate these hypotheses, we propose the following Specific Aims: 1. To define the early virologic, immunologic, and pathologic events following IVAG SIV infection of naive, unvaccinated rhesus monkeys; 2. To evaluate the capacity of adenovirus vector-based vaccines to impact the early events following IVAG SIV infection of rhesus monkeys;and 3. To assess the capacity of poxvirus vector-based vaccines to impact the early events following IVAG SIV infection of rhesus monkeys.

Public Health Relevance

The earliest events of mucosal HIV-1 infection in humans remain largely undefined, given the short duration and asymptomatic nature of the eclipse phase of HIV-1 infection. An improved understanding of the earliest events following IVAG SIV infection of rhesus monkeys will yield insights into critical viral vulnerabilities during the transmission process that can be exploited by vaccine-elicited immune responses. Such knowledge will lead to the development of improved next generation HIV-1 vaccine strategies.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-LR-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Okoye, Afam A; Hansen, Scott G; Vaidya, Mukta et al. (2018) Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat Med 24:1430-1440
Abbink, Peter; Larocca, Rafael A; Dejnirattisai, Wanwisa et al. (2018) Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. Nat Med 24:721-723
Walters, Lucy C; Harlos, Karl; Brackenridge, Simon et al. (2018) Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat Commun 9:3137
Aid, Malika; Abbink, Peter; Larocca, Rafael A et al. (2017) Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. Cell 169:610-620.e14
Abbink, Peter; Larocca, Rafael A; Visitsunthorn, Kittipos et al. (2017) Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci Transl Med 9:
Keele, Brandon F; Li, Wenjun; Borducchi, Erica N et al. (2017) Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nat Commun 8:15740
Barouch, Dan H; Thomas, Stephen J; Michael, Nelson L (2017) Prospects for a Zika Virus Vaccine. Immunity 46:176-182
Ackerman, Margaret E; Barouch, Dan H; Alter, Galit (2017) Systems serology for evaluation of HIV vaccine trials. Immunol Rev 275:262-270
McMichael, Andrew J; Picker, Louis J (2017) Unusual antigen presentation offers new insight into HIV vaccine design. Curr Opin Immunol 46:75-81
Tomalka, Jeffrey; Ghneim, Khader; Bhattacharyya, Sanghamitra et al. (2016) The sooner the better: innate immunity as a path toward the HIV cure. Curr Opin Virol 19:85-91

Showing the most recent 10 out of 57 publications